Exelixis, Inc.

Mei Pharma, Inc.

Genentech, Inc.

Other

University of Texas System

University of Washington

Mmv Medicines for Malaria Venture

Medicines for Malaria Venture (mmv)

Alla Chem, LLC

Monash University

Glaxosmithkline Investigacion Y Desarrollo, S.l.

David J Matthews

S David Brown

James A Wells

Peter Lamb

Henry Bernard Lowman

Dennis J Henner

Steven H Bass

Mark Zoller

Alison Joly

Michael Martin Ollmann

Susan A Charman

Jean-Michel Andre Vernier

John M Nuss

Neel Kumar Anand

Harvey F Lodish

Tsze Tsang

Timothy Patrick Forsyth

William Charles Ripka

Csaba J Peto

David M Floyd

James William Leahy

Kenneth D Rice

Michael Peter Ross

Larry Wayne Mann

Abigail R Kennedy

Jeff Z Chen

Nikolay Filippovich Savchuk

Grace Mann

Tai Phat Huynh

Longcheng Wang

Craig Stacy Takeuchi

Larisa Dubenko

Erick Wang Co

Ilya Okun

Chris Allen Buhr

Lisa Esther Dalrymple

Sunghoon Ma

Sergey Epshteyn

Xian Shi

Mohamed Ibrahim

Tae-Gon Baik

Sumalee Kamchonwongpaisan

Alexander Khvat

Sergey Yevgenievich Tkachenko

Yongyuth Yuthavong

Ronald Greene

Lisa J Garrard

Kevin Patrick Keegan

Thomas J Stout

Zerom Tesfai

Lutz B Giebel

William Charman

Kevin Luke Schnepp

Patrick O'Connor

Margaret Phillips

Geetha Shankar

Frauke Bentzien

Jeremy Burrows

Pradipsinh K Rathod

Alka Marwaha

Ramesh Gujjar

Baili Chen

John May

Xin Liu

Penchit Chitnumsub

Hong Wu

Tirayut Vilaivan

Bongkoch Tarnchompoo

Chawanee Thongpanchang

Jose Coteron-Lopez

Jirundon Yuvaniyama

Livia Vivas

Sanjay Babu Katiyar

Borys Rogovoy

Nicole Miller

Bongkoch Tarchompoo

Tirayut Vilavain

Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.

(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases

Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases. 

Inhibitors of parasitic dihydroorotate dehydrogenase enzyme (DHOD) are candidate therapeutics for treating malaria. Illustrative of such therapeutic agents include the compound: and a triazolopyrimidine class of compounds that conform to Formula IX: and their solvates, stereoisomers, tautomers and pharmaceutically acceptable salts.

Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase

This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL&#xae; from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE&#xae; from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN&#xae;, VINCASAR PFS&#xae;, VCR), Vinblastin (VELBAN&#xae;, VELSAR&#xae;) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.

Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents

The present invention relates to novel compounds that are inhibitors of wild type and mutant dihydrofolate reductase (DHFR) of, which are useful for the treatment of malaria. It also relates to processes of making and using such compounds. The antimalarial compounds of the present invention have low toxicity to a host infected with the malarial parasite, and are potent when administered in pharmaceutical compositions.

Antimalarial compounds with flexible side-chains

The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments. (Formula I) 

Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary diseases and disorders.

Antagonist of smoothened

The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments. 

Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer

This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.

Protein kinase modulators and methods of use

A computer-operated graphical content management interface is provided wherein a user can navigate to and view data objects by moving a perceived distance relative to the data objects, either closer to or farther from the user.

Apparatus and method of managing data objects

Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.

Methods of screening for agents that modulate the interaction of human ECT2 polypeptide with an ECT2 binding target

Growing community of inventors

San Francisco, CA, United States of America

David J Matthews